Salipro Biotech has entered into a collaboration and license agreement with Sanofi to advance discovery programs.
Salipro Biotech announced on Nov. 8, 2022 that it has entered into a research collaboration and license agreement with Sanofi on the discovery of therapeutic biologics against a challenging drug target.
The collaboration will combine Salipro Biotech’s expertise and its Salipro platform technology to develop stable antigens of GPCRs, ion channels, and transporters with Sanofi’s drug discovery programs to move forward the generation of biologics.
“We are excited to work closely with the innovative team at Sanofi to accelerate their drug discovery efforts against a selected membrane protein drug target,” said Jens Frauenfeld, CEO of Salipro Biotech, in a press release. “Combining our expertise and platform technology to generate Salipro-stabilized drug targets with Sanofi’s expertise in biologics discovery and development will open up entirely new possibilities to make the undruggable druggable for Sanofi’s biopharmaceutical pipeline.”
Source:
